Third Harmonic Bio, Inc. ( (THRD) ) has released its Q3 earnings. Here is a breakdown of the information Third Harmonic Bio, Inc. presented to ...

THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

1 Day THRD 2.13% DJIA 0.97% Russell 2K 2.10% Health Care/Life Sciences 1.71% ...

Conner Edward R., the Chief Medical Officer of Third Harmonic (NASDAQ:HLIT) Bio, Inc. (NASDAQ:THRD), recently executed a series of stock transactions, according to a recent filing. On October 28 ...

Third Harmonic Bio, Inc. (NASDSAQ: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, ...

Short interest in Third Harmonic Bio Inc (NASDAQ:THRD) increased during the last reporting period, rising from 2.21M to 2.78M. This put 14.98% of the company's publicly available shares short.

SAN JOSE, Calif., Oct. 14, 2024 /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced it will release its third quarter 2024 financial results after the market close on Monday, October 28 ...

SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, ...